Teewinot Life Sciences is a privately held biopharmaceutical company based in Tampa, Florida. The company focuses on the biosynthetic production of pure pharmaceutical grade cannabinoids through its patented production process known as CannSynthesis. By combining synthetic biology, biocatalysis, chemical synthesis, bioinformatics, and metabolomics, the cannabinoids produced by Teewinot have the identical chemical structure of cannabinoids found in the Cannabis plant.
Teewinot's technology is also used to custom manufacture pharmaceutical drugs, new biological products including neutraceuticals, cosmeceuticals, and medical veterinary product for other research and development organizations. In addition, it manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids.
In October 2018, the company announced the launch of a new subsidiary, Canalis Pharmaceuticals, a drug discovery and development company that uses cannabinoids and their NCEs (New Chemical Entities) as small molecule libraries for identifying compounds with human therapeutic activity.
Teewinot Life Science raises a $12,300,000 series B round from Tuatara Capital.
President, Chairman, & CEO
Dr. Malcolm Kavarana
Chief Scientific Officer & Senior Director, Intellectual Property.
Eric A. Walker
Chief Information Officer
Teewinot Life Sciences Corporation's Subsidiary, Teewinot Technologies, Ltd. Announced Today: Grant of a New Patent with Broad Claims to Biosynthetic Production of Cannabinoid Pharmaceuticals | Markets Insider
Teewinot Life Sciences' Patented Biosynthetic Tech Cuts Costs and Produces Clinical-Grade Cannabinoids - CannabisNewsWire